Overview

MEK Inhibitor Combined With Anlotinib in the Treatment of KRAS-mutated Advanced Non-small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

This is a phase I, exploratory study. The study plans to enroll 30 eligible patients to receive MEK inhibitor combined with anlotinib. Tumor assessments will be performed at Screening with follow-up at Week 4 ±1 week from the date of the first cycle treatment, and then every 4 weeks ±1 week until confirmed objective disease progression. Patients will participate in safety follow-up after the first course of treatment, until within 3 months after stopping the drug due to PD or toxicity. Blood samples will be collected at baseline and each periodic assessment for biomarker analysis and screening.

Phase:

Phase 1

Details

Lead Sponsor:

Shanghai Chest Hospital

Treatments:

Trametinib